×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
PR Newswire
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing...
1 month ago
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate ...
PR Newswire
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to...
2 months ago
Brii Biosciences Full Year 2023 Earnings: Beats Expectations
Simply Wall Street
Brii Biosciences ( HKG:2137 ) Full Year 2023 Results Key Financial Results Revenue: CN¥416.7m (up 241% from FY 2022...
1 month ago
VBI Vaccines, Brii Biosciences expand Hepatitis B partnership
Pharmaceutical Technology
VBI Vaccines has announced the expansion of its HBV partnership with Brii Bio to address prevention and treatment of the disease.
9 months ago
Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts ...
Yahoo Finance
The postpartum depression market is expected to show positive growth, mainly attributed to the increasing incident cases and also,...
5 months ago
Brii expands hepatitis B partnership with VBI in deal worth $437M
BioWorld MedTech
In a move to address both prevention and treatment of hepatitis B virus (HBV), Brii Biosciences Ltd. has acquired from VBI Vaccines Inc. a...
9 months ago
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results USA - English - APAC - English
PR Newswire
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several...
8 months ago
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
PR Newswire
PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to...
3 months ago
Brii Biosciences Closes US$155 Million Series C Financing
Business Wire
Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs...
37 months ago
Brii Bio introduces Covid-19 combination therapy in China
Pharmaceutical Technology
In a Phase III trial, the antibody combination offered a statistically significant 80% decline in hospitalisation and death. July 7, 2022.
21 months ago